Search research articles
Contact Us
Filters
Showing results (321-330 of 386) with videos related to
Page
of 39
Sort By:
International Journal of Cancer
|
February 4, 2018
Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models
Talia Golan, Chani Stossel, Dikla Atias, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 24, 2015
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†
V Speirs, G Viale, K Mousa, et al.
British Journal of Cancer
|
October 5, 2013
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial
J M S Bartlett, C L Brookes, T Piper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2017
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial
H R Ali, A Dariush, J Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
H M Earl, L Hiller, J A Dunn, et al.
The Lancet. Oncology
|
September 16, 2011
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
Angelo Di Leo, Christine Desmedt, John M S Bartlett, et al.
Archives of Pathology & Laboratory Medicine
|
May 31, 2018
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2018
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, et al.
Cancer Research Communications
|
October 22, 2025
Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Anil Abraham Joy, Nicholas Cheng, Karen A Gelmon, et al.
Breast (Edinburgh, Scotland)
|
July 9, 2025
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?
Ana-Alicia Beltran-Bless, Gregory R Pond, Jane Bayani, et al.
Page
of 39
Search research articles
Search
Showing results (321-330 of 386) with videos related to
Sort By:
Page
of 39
International Journal of Cancer
|
February 4, 2018
Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models
Talia Golan, Chani Stossel, Dikla Atias, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 24, 2015
Prognostic and predictive value of ERβ1 and ERβ2 in the Intergroup Exemestane Study (IES)-first results from PathIES†
V Speirs, G Viale, K Mousa, et al.
British Journal of Cancer
|
October 5, 2013
Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial
J M S Bartlett, C L Brookes, T Piper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 20, 2017
Lymphocyte density determined by computational pathology validated as a predictor of response to neoadjuvant chemotherapy in breast cancer: secondary analysis of the ARTemis trial
H R Ali, A Dariush, J Thomas, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 2, 2017
Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
H M Earl, L Hiller, J A Dunn, et al.
The Lancet. Oncology
|
September 16, 2011
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data
Angelo Di Leo, Christine Desmedt, John M S Bartlett, et al.
Archives of Pathology & Laboratory Medicine
|
May 31, 2018
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 31, 2018
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C Wolff, M Elizabeth Hale Hammond, Kimberly H Allison, et al.
Cancer Research Communications
|
October 22, 2025
Continuous versus Standard Palbociclib Treatment and Molecular Profiling of Solid Tissues and Liquid Biopsies in the CCTG MA.38 Trial in Advanced Breast Cancer
Anil Abraham Joy, Nicholas Cheng, Karen A Gelmon, et al.
Breast (Edinburgh, Scotland)
|
July 9, 2025
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?
Ana-Alicia Beltran-Bless, Gregory R Pond, Jane Bayani, et al.
Page
of 39